Video

Dr. Grothey on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

Axel Grothey, MD, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high (MSI-H) and mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

The KEYNOTE-177 trial was a randomized study examining the use of first-line pembrolizumab (Keytruda) versus chemotherapy—specifically investigator's choice of doublet chemotherapy with or without a biologic agent—in patients with MSI-H/dMMR mCRC, Grothey explains. This patient subgroup is rare, comprising only about 4%to5% of allCRCs, according to Grothey. However, once identified, this patient population haseffective treatment options through the addition of immunotherapy.

In the trial, which comprised 307 patients, data showed thatpembrolizumabled tomarked improvementsin progression-free survivalover chemotherapy, Grothey concluded.

Related Videos
Aparna Parikh, MD
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Kimmie Ng, MD, MPH
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Kimmie Ng, MD, MPH
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Richard Kim, MD
Arvind N. Dasari, MD, MS